{Reference Type}: Journal Article
{Title}: The cost-effectiveness of a co-managed care model for elderly hip fracture patients in China: a modelling study.
{Author}: Xu L;Yang M;Zhang X;Zhang J;He J;Wen L;Wang X;Shi Z;Hu S;Sun F;Gong Z;Sun M;Peng K;Ye P;Ma R;Wu X;Chen M;Jan S;Ivers R;Tian M;Si L;
{Journal}: Lancet Reg Health West Pac
{Volume}: 49
{Issue}: 0
{Year}: 2024 Aug
{Factor}: 8.559
{DOI}: 10.1016/j.lanwpc.2024.101149
{Abstract}: <B>UNASSIGNED: </B>The clinical effectiveness of multidisciplinary co-managed care for hip fracture patients in China has been demonstrated in a multicenter non-randomized controlled study. This study aims to estimate the cost-effectiveness of the co-managed care.<BR><B>UNASSIGNED: </B>The study is based on a multicenter clinical trial (n = 2071) in China. We developed a state transition microsimulation model to estimate the cost-effectiveness of the co-managed care compared with usual care for hip fracture patients from healthcare system perspective. The costs incorporated into the model included hospitalization costs, post-discharge expenses, and secondary fracture therapy costs. Effectiveness was measured using quality-adjusted life years (QALYs). Costs and effects were discounted at 5% annually. A simulation cycle length of 1-year and a lifetime horizon were employed. The cost-effectiveness threshold was established at USD 37,118. To address uncertainties, one-way deterministic sensitivity analysis and probabilistic sensitivity analysis were conducted.<BR><B>UNASSIGNED: </B>In the base case analysis, the co-managed care group had a lifetime cost of USD 31,571 and achieved an effectiveness of 3.22 QALYs, whereas the usual care group incurred a cost of USD 27,878 and gained 2.85 QALYs. The incremental cost-effectiveness ratio was USD 9981 per QALY gained; thus the co-managed care model was cost-effective. The cost-effectiveness was sensitive to the age of having hip fractures and hospitalization costs in the intervention group.<BR><B>UNASSIGNED: </B>The co-managed care in hip fracture patients represents value for money, and should be scaled up and prioritized for funding in China.<BR><B>UNASSIGNED: </B>The study is supported by Capital's Funds for Health Improvement and Research (2022-1-2071, 2018-1-2071).